No­var­tis ends mid-stage IPF tri­al, will keep test­ing drug in PAH

No­var­tis has ter­mi­nat­ed a mid-stage tri­al of an oral treat­ment can­di­date for id­io­path­ic pul­monary fi­bro­sis, the com­pa­ny con­firmed to End­points News.

The Swiss phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER